文献速递真菌感染

印度毛霉病多中心观察研究:流行病学、危险因素、管理与结局

A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India.
PubMed 文献 · Clin Microbiol Infect · 2019-12-04

该研究为印度12中心前瞻性观察研究,纳入465例确诊毛霉病患者,记录人口学、微生物学、易感因素、管理及90天死亡率并分析死亡危险因素。结果显示糖尿病为最主要易感因素(73.5%),90天死亡率为52%,联合手术与药物管理关联更好生存。

要点

  • 糖尿病是各型毛霉病的主要易感因素(342/465,73.5%)。
  • 90天死亡率为52%(242/465),播散性及鼻眶-脑扩展型死亡风险更高。
  • 联合手术与药物管理关联更好生存,但管理中仍存在多处差距。

核心结论

  • 糖尿病是所有型别毛霉病的主要易感因素,联合手术与药物管理关联更好结局。
  • 研究中识别出多种罕见毛霉目真菌,值得进一步评估。

研究设计与样本

  • 前瞻性观察研究,纳入印度12个中心连续确诊毛霉病患者465例,记录人口学、微生物学、易感因素、管理及90天死亡率并分析死亡危险因素。

主要发现

  • 鼻眶型最常见(315/465,67.7%),其次为肺型(62/465,13.3%)、皮肤型(49/465,10.5%)及其他。
  • 易感因素包括糖尿病(342/465,73.5%)、恶性肿瘤(42/465,9.0%)、移植(36/465,7.7%)等。
  • 病原以根霉属最常见(231/290,79.7%),其次为Apophysomyces variabilis(23/290,7.9%)及多种罕见毛霉目真菌。
  • 62.2%(289/465)接受手术治疗,81.9%(381/465)以两性霉素B为主要治疗,53例(11.4%)联合泊沙康唑。
  • 抗真菌治疗不适当者占7.6%(30/394);90天死亡率为52%(242/465)。

关键数值与推荐

  • 多因素分析显示播散性及鼻眶型(伴脑扩展)毛霉病、症状持续时间较短、抗真菌治疗持续时间较短、使用脱氧胆酸两性霉素B(对比脂质体)为死亡的独立危险因素。
  • 联合手术与药物管理关联更好生存。

临床怎么用

  • 对糖尿病患者应警惕毛霉病,尤其是鼻眶型表现。
  • 治疗应尽早联合手术与抗真菌药物,并注意选择脂质体两性霉素B而非脱氧胆酸剂型。
  • 需关注抗真菌治疗适当性及疗程,避免治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the epidemiology, management and outcome of individuals with mucormycosis; and to evaluate the risk factors associated with mortality. METHODS: We conducted a prospective observational study involving consecutive individuals with proven mucormycosis across 12 centres from India. The demographic profile, microbiology, predisposing factors, management and 90-day mortality were recorded; risk factors for mortality were analysed. RESULTS: We included 465 patients. Rhino-orbital mucormycosis was the most common (315/465, 67.7%) presentation followed by pulmonary (62/465, 13.3%), cutaneous (49/465, 10.5%), and others. The predisposing factors included diabetes mellitus (342/465, 73.5%), malignancy (42/465, 9.0%), transplant (36/465, 7.7%), and others. Rhizopus species (231/290, 79.7%) were the most common followed by Apophysomyces variabilis (23/290, 7.9%), and several rare Mucorales. Surgical treatment was performed in 62.2% (289/465) of the participants. Amphotericin B was the primary therapy in 81.9% (381/465), and posaconazole was used as combination therapy in 53 (11.4%) individuals. Antifungal therapy was inappropriate in 7.6% (30/394) of the individuals. The 90-day mortality rate was 52% (242/465). On multivariate analysis, disseminated and rhino-orbital (with cerebral extension) mucormycosis, shorter duration of symptoms, shorter duration of antifungal therapy, and treatment with amphotericin B deoxycholate (versus liposomal) were independent risk factors of mortality. A combined medical and surgical management was associated with a better survival. CONCLUSIONS: Diabetes mellitus was the dominant predisposing factor in all forms of mucormycosis. Combined surgical and medical management was associated with better outcomes. Several gaps surfaced in the management of mucormycosis. The rarer Mucorales identified in the study warrant further evaluation.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2019. PMID: 31811914. doi:10.1016/j.cmi.2019.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。